載入...
The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer treatment. Because of dysregulated activation of the immune system, patients with autoimmune disease (AID) are usually excluded from ICI clinical trials. Due to a large number of cancer patients with preexisting...
Na minha lista:
| 發表在: | Front Oncol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7937882/ https://ncbi.nlm.nih.gov/pubmed/33692958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.625872 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|